Paradigm, Galaxy back Sonnet Bio's $888M pivot to Hyperliquid treasury strategy

Sonnet BioTherapeutics, a publicly listed biotech firm, has announced a definitive merger agreement with Rorschach I LLC, a newly formed entity backed by Atlas Merchant Capital and other crypto-focused investors, including Paradigm Ventures. According to a July 14 statement, the merged company will adopt a new name, Hyperliquid Strategies, Inc.

Source: cryptoslate.com

Related symbols: GLXYUSD